Viking Therapeutics, Inc. - Common Stock (VKTX)

One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet.

One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.

The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.

This biotech might have a bright future, but it'll need to survive against the incumbents to do so.

The stock is known to soar on good news.

Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug.

That would be an impressive run if it could get there soon.

These stocks are better bets to skyrocket than the much-hyped rocket stock.

Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare.

The GLP-1 drug market is massive and still growing fast. Investing in a promising growth stock in the space could lead to significant returns.

The drugmaker is looking to challenge the leaders in the weight loss market.

Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.

Shoppers keep coming back to these companies.

Viking stock is known for soaring after positive news.

If you look beyond the upside potential, there's still plenty of risk to navigate past.

This particular sector may suit cautious and aggressive investors.

The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals.

An upcoming trial result could change how investors think about the weight-loss drug market.

Most of the market's best-known growth names are overbought at this time. That's not the case for several off-the-radar alternatives.

These players are seeing exciting results in clinical trials.

It may be too late for Viking to take on the "dark horse" role in the GLP-1 wars.

The pharma giant is taking steps to expand its portfolio.

Viking's strong obesity drug data continues fueling acquisition speculation.

Long-time shareholders are already pretty satisfied with these companies, but there might be even more upside ahead.

Demand for weight loss drugs may fuel growth for more than one player.